ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.90
-0.22%
Dow Jones
40,954.48
1.85%
Gold vs US Dollar
2,467.735
1.88%
Brent Oil
83.135
-1.43%
Bitcoin
64,871.68
0.03%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) News

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateTimeSourceHeadlineSymbolCompany
15/08/200713:00PR Newswire (US)Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/08/200714:00PR Newswire (US)Allos Therapeutics Reports Second Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/07/200713:00PR Newswire (US)Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/06/200714:30PR Newswire (US)Allos Therapeutics Selected to Join Russel 3000 IndexNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/06/200711:30PR Newswire (US)Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From BreastNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/05/200722:01PR Newswire (US)Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseasNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/05/200722:55PR Newswire (US)Allos Therapeutics Files Shelf Registration StatementNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/05/200713:30PR Newswire (US)Allos Therapeutics Reports First Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/05/200718:21PR Newswire (US)Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/04/200713:00PR Newswire (US)Allos Therapeutics Appoints Dr. Jeffrey R. Latts to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/04/200713:30PR Newswire (US)Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European CommissionNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/03/200712:00PR Newswire (US)Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical OfficerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/03/200712:00PR Newswire (US)Allos Therapeutics Reports Fourth Quarter and 2006 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/02/200713:00PR Newswire (US)Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/02/200713:00PR Newswire (US)Allos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/02/200716:01PR Newswire (US)Allos Therapeutics Announces Closing of Common Stock OfferingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/01/200711:00PR Newswire (US)Allos Therapeutics Announces Pricing of Underwritten Offering of 9,000,000 Shares of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200720:19PR Newswire (US)Allos Therapeutics to Present at the 2007 JP Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200712:05PR Newswire (US)Allos Therapeutics Appoints William R. Ringo to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200712:00PR Newswire (US)Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in PatienNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/12/200616:46PR Newswire (US)Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel AnNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/11/200613:00PR Newswire (US)Allos Therapeutics Added to NASDAQ Biotech IndexNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/11/200613:15PR Newswire (US)Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates DecreaseNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/11/200618:56PR Newswire (US)Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas aNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/11/200617:00PR Newswire (US)Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential ChemorNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/11/200612:30PR Newswire (US)Allos Therapeutics Reports Third Quarter 2006 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/11/200621:00PR Newswire (US)Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/10/200617:30PR Newswire (US)Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/10/200612:29PR Newswire (US)Allos Therapeutics Announces ENRICH Trial UpdateNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/10/200614:00PR Newswire (US)Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Your Recent History

BIT
UC33YP
Unicredit Bank
TSX
TPX.A
Molson Coors Canada
BIT
GLAG
Spdr Bbg Barclays Global...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved